VIVALDI: A Pilot Study of the LSD1 Inhibitor Iadademstat in Combination with Azacitidine and Venetoclax in Newly Diagnosed Acute Myelogenous Leukemia Patients with Suboptimal Response to the Standard of Care Treatment.
Sponsor: Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias
Phase:
Disease: Newly diagnosed acute myeloid leukemia
EU trial number: 2026-527464-32-00
Population: Patients with newly diagnosed acute myeloid leukemia showing suboptimal response to standard azacitidine and venetoclax treatment; the VIVALDI pilot investigates adding the LSD1 inhibitor iadademstat. CTIS lists a planned Spanish enrollment of 30 patients.
Register Investigator Interest
Interested in offering this trial to suitable patients?